Tag: 2018 ASCO annual meeting

Home / 2018 ASCO annual meeting

Categories

Pabosini plus cetuximab for head and neck cancer treatment with 70% focal reduction

According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent  re...
2018-asco-annual-meeting

Scan the code